LONDON, Nov 23 (Reuters) - AstraZeneca's chief
executive officer Pascal Soriot said on Monday that the lower
first dose of its experimental COVID-19 vaccine meant more
people can be vaccinated more quickly, as the British drugmaker
unveiled interim late-stage trial results.
"Being able to vaccinate more people faster is a really a
big plus," he told a briefing.
The British drugmaker said on Monday its vaccine for the
novel coronavirus could be around 90% effective without any
serious side effects.
The vaccine developed by Oxford University was most
effective when it was administered as a half dose followed by a
full dose at least one month apart, rather than as two full
doses at least one month apart.
(Reporting by Kate Kelland, Guy Faulconbridge and Kate Holton;
Writing by Josephine Mason; Editing by Edmund Blair)